Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more


(Plasmid #133043)


Item Catalog # Description Quantity Price (USD)
Plasmid 133043 Standard format: Plasmid sent in bacteria as agar stab 1 $85

This material is available to academics and nonprofits only.


  • Vector backbone
  • Vector type

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
  • Growth Strain(s)
    NEB Stable
  • Copy number
    High Copy


  • Gene/Insert name
    Tet repressor
  • gRNA/shRNA sequence
  • Tag / Fusion Protein
    • Cerulean

Resource Information

  • A portion of this plasmid was derived from a plasmid made by
    Dmitri Wiederschain (Addgene plasmid # 21915) and Sriram Neelamegham (Addgene plasmid # 64847)

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    SiC-V2-Cas9G7 was a gift from Sriram Neelamegham (Addgene plasmid # 133043 ; ; RRID:Addgene_133043)
  • For your References section:

    Doxycycline-Dependent Self-Inactivation of CRISPR-Cas9 to Temporally Regulate On- and Off-Target Editing. Kelkar A, Zhu Y, Groth T, Stolfa G, Stablewski AB, Singhi N, Nemeth M, Neelamegham S. Mol Ther. 2019 Sep 12. pii: S1525-0016(19)30409-5. doi: 10.1016/j.ymthe.2019.09.006. 10.1016/j.ymthe.2019.09.006 PubMed 31601489